1-5 of 5
Yanze Shi
Close
Sort by
Journal Articles

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Xian Zhang, Junfang Yang, Jingjing Li, Yanze Shi, Yunchao Su, Ying Liu, Min Ba, Yan Wu, Wenqian Li, Jianqiang Li, Peihua Lu
Journal: Blood
Blood (2021) 138 (Supplement 1): 1741.
https://doi.org/10.1182/blood-2021-146425
Published: 2021
Journal Articles

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Jiasheng Wang, Yue Liu, Junfang Yang, Jingjing Li, Gailing Zhang, MD, Yanze Shi, Jiujiang He, Dan Song, Wenqian Li, Shulian Xia, Min Zhang, Zhixiao Zhou, Lemei Jia, Hongli Zheng, Xin Lin, Peihua Lu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-136833
Published: 2020
Journal Articles

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Liyuan Qiu, Xin-An Lu, Fei Wu, Jianqiang Li, PhD, Dandan Chen, Xiangqun Li, Ziyu Li, Jingjing Li, Peihua Lu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–6.
https://doi.org/10.1182/blood-2020-137299
Published: 2020
Journal Articles

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Jingjing Li, Xinan Lu, Jianqiang Li, PhD, Xiangqun Li, Zhongwei Xu, Ziyu Li, Peihua Lu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-136897
Published: 2020
Journal Articles

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Junfang Yang, MD, Yanze Shi, Dan Song, Jingjing Li, Xin-an Lu, PhD, Fei Wu, Jianqiang Li, Ph. D., Dandan Chen, Xiangqun Li, Zhongwei Xu, Shuqiang Liu, Ziyu Li, Kui YIng, Wenya Wang, Peihua Lu
Journal: Blood
Blood (2019) 134 (Supplement_1): 224.
https://doi.org/10.1182/blood-2019-125503
Published: 2019